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Efficacy and Safety of Oxaliplatin and Gemcitabine with
Bevacizumab in Advanced Non-small Cell Lung Cancer
Rogerio Lilenbaum, MD,* Luis Raez, MD,† Jennifer Tseng, MD,‡ Leonard Seigel, MD,*
and Enrique Davila, MD*
Introduction: We conducted a multicenter phase II study to eval-
uate the efficacy and safety of oxaliplatin and gemcitabine with
bevacizumab in patients with advanced non-small cell lung cancer
(NSCLC).
Methods: Patients with chemotherapy-naive, nonsquamous, stage
IIIB or IV NSCLC received gemcitabine 1000 mg/m2 on days 1 and
8, oxaliplatin 130 mg/m2 on day 1, and bevacizumab 15 mg/kg on
day 1 every 21 days for 4 cycles. Patients with stable disease or
response received maintenance bevacizumab every 3 weeks until
progression. Primary end point was median time to progression
(TTP).
Results: Nineteen of 44 eligible patients had partial response in the
intent-to-treat analysis for an objective response rate of 43% (95%
confidence interval [CI], 26.3–60.1%); 16 patients had stable dis-
ease for a disease control rate of 80% (95% CI, 72.0–87.0%).
Median TTP was 5.5 months (95% CI, 3.8–6.9 months), which
approached that seen in phase III studies. Median survival was 13.7
months (95% CI, 7.3–21.8 months). The most common grade 3 or 4
adverse events were hypertension (11%), neutropenia (9%), diarrhea
(7%), dyspnea (7%), and thromboembolic events (7%). Pulmonary
hemorrhage was not observed.
Conclusions: The results of this phase II study suggest that oxali-
platin and gemcitabine with bevacizumab was active and reasonably
well tolerated. Median TTP approached that in phase III studies.
This combination represents another treatment option for advanced
NSCLC.
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Combination chemotherapy has become the standard treat-ment for patients with advanced non-small cell lung
cancer (NSCLC).1 Only minor differences have been detected
among platinum-based doublets in large randomized phase III
studies.2–4 Oxaliplatin with gemcitabine is a theoretically
attractive doublet because of its synergy in human cancer cell
lines5 and favorable safety profile in phase II studies.6–8
Specifically, oxaliplatin is associated with less nephrotoxicity
than cisplatin9 and less myelosuppression than carboplatin.10
Preliminary clinical studies of this combination have yielded
efficacy outcomes in the range of other commonly used
platinum-based doublets.6–8 Furthermore, a recent phase III
study indicated that the addition of bevacizumab to a standard
regimen such as carboplatin and paclitaxel significantly im-
proved response rate, TTP, and survival.11
Based on this rationale, we conducted a phase II study
to investigate the efficacy and safety of oxaliplatin and
gemcitabine with bevacizumab as first-line therapy in eligible
patients with advanced NSCLC. The dosages of oxaliplatin
and gemcitabine were based on a phase I study12 in which the
combination was well tolerated with primarily hematologic
toxicity at the maximum tolerated dose; sensory neuropathy
was relatively uncommon and reversible. Four cycles of the
3-drug combination were administered and followed by
maintenance bevacizumab. The duration of induction therapy
was based on randomized studies in which 3 or 4 cycles
resulted in less toxicity and provided benefits comparable to
those of 6 or more cycles.13–15 The dosage and schedule of
bevacizumab were based on the phase III study.11
MATERIALS AND METHODS
Eligibility
Patients were eligible if they had histologically or
cytologically confirmed advanced (stage IIIB with malignant
pleural effusion or stage IV or recurrent disease) nonsqua-
mous NSCLC and had not received prior systemic treatment.
Patients had to have measurable disease without central
nervous system metastases and an Eastern Cooperative On-
cology Group (ECOG) performance status of 0 or 1. Patients
also had to have adequate hematologic (absolute neutrophil
count 1500/L and platelets 100,000/L), hepatic (total
bilirubin 1.5 mg/dL and transaminases 5  the upper
limit of normal), and renal function (serum creatinine1.5
upper limit of normal and urinalysis 1 protein). Women
of childbearing potential and sexually active males had to use
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contraception. Exclusion criteria were pregnancy or lactation;
unresolved adverse events from radiation therapy; deep-vein
thrombosis or pulmonary embolus within 1 year; ongoing
therapeutic anticoagulant; uncontrolled hypertension; serious
nonhealing wound ulcer, bone fracture, or major surgical
procedure within 3 weeks; history of gross hemoptysis; prior
malignancy; or other medical conditions that would limit
compliance with study requirements. All patients provided
written informed consent. The Institutional Review Board
approved the study, which was conducted in accordance with
federal and institutional guidelines.
Treatment Plan and Evaluation
This was an open-label phase II study. Patients received
intravenous (IV) gemcitabine 1000 mg/m2 over 30 minutes
on days 1 and 8 followed by IV oxaliplatin 130 mg/m2 over
2 hours on day 1 followed by IV bevacizumab 15 mg/kg over
90 minutes on day 1. Anaphylaxis precautions were observed
during bevacizumab administration. If bevacizumab was well
tolerated, the second infusion was shortened to 60 minutes
and subsequent infusions to 30 minutes. Antiemetic admin-
istration was allowed at the discretion of the investigators.
Granulocyte colony-stimulating factor could also be admin-
istered according to American Society of Clinical Oncology
guidelines.16 Treatment was administered every 21 days for a
maximum of 4 cycles. Patients with complete or partial
response or stable disease after 4 cycles received maintenance
IV bevacizumab 15 mg/kg every 3 weeks until relapse or
progression.
Toxicity was assessed every cycle using National Can-
cer Institute Common Toxicity Criteria Version 3.0. Dose
modifications were based on worst toxicity for any organ
system for the previous cycle. Dose escalations were not
permitted. The gemcitabine dose was first reduced to 900
mg/m2 and, for second occurrence of selected toxicities, to
800 mg/m2. The oxaliplatin dose was reduced to 100 mg/m2.
For absolute neutrophil count 500/L for 7 days or
febrile neutropenia, both drugs were delayed until recovery to
1000/L and administered at the first reduction level. For
platelets 50,000/L, gemcitabine was delayed until recov-
ery to 75,000/L and administered at the first reduction
level. For second occurrence of platelets 50,000/L, both
drugs were delayed until recovery, and gemcitabine was
administered at the second reduction level and oxaliplatin at
the first reduction level. Similar reductions and delays were
specified for gemcitabine on day 8. For nonhematologic
toxicities other than nausea, vomiting, and alopecia, both
drugs were reduced to the first level for grade 3 toxicity and
stopped for grade 4 toxicity. In addition, oxaliplatin was
reduced for paresthesia or dysesthesia that was grade 2 and
persistent or grade 3, and was stopped for grade 3 or 4 acute
hypersensitivity or anaphylactic reaction; the infusion dura-
tion was prolonged to 4 to 6 hours for acute laryngopharyn-
geal dysesthesia. Bevacizumab was generally delayed until
recovery from grade 3 toxicity and discontinued upon second
occurrence of grade 3 toxicity or first occurrence of grade 4
toxicity, such as hemorrhage, uncontrolled hypertension, pro-
teinuria, or venous thrombosis.
Patients were evaluated at baseline and at the beginning
of each cycle. Evaluations generally included history, phys-
ical examination, vital signs, complete blood count with
differential and platelet count, serum chemistries, urinalysis,
and assessment of ECOG performance status and neurologic
function. Computed tomography (CT) scans of potential
disease areas and brain imaging by CT scan or magnetic
resonance imaging were performed at baseline. If clinically
indicated, bone scan, skeletal survey, or magnetic resonance
imaging was performed at the beginning of each cycle. CT
scans were performed for tumor assessment after cycles 2 and
4 and then every 12 weeks during maintenance therapy.
Response Evaluation Criteria in Solid Tumors17 were used to
categorize response to treatment as complete response, partial
response, stable disease, or progressive disease.
The primary end point was median TTP, defined as
time from registration to tumor progression or death. TTP
was censored at the last known progression-free date for
patients who remained on or were removed from study
without objective tumor progression, received nonstudy an-
titumor treatment, or were lost to follow-up without disease
progression. Patients who completed therapy without disease
progression were censored on the last follow-up date. Sec-
ondary endpoints were response rates, median duration of
survival, and adverse events.
Statistical Analysis
Target sample size was 50 evaluable patients, which
yielded statistical power of 80% to detect the difference
between the null (median TTP of 4.6 months) and alternative
(median TTP of 6.7 months) hypotheses, with an exponential
maximum likelihood estimate and a one-sided significance
level of 0.05.18 Kaplan-Meier method was used to estimate
TTP and survival.19 Descriptive statistics were used for base-
line characteristics and secondary endpoints.
Study populations were defined prospectively. The
intent-to-treat population included all eligible patients,
whether or not they received any study drug. The safety
population included all patients who received at least 1 dose
of any study drug. The efficacy-evaluable population in-
cluded all patients who received at least 2 cycles of treatment
with at least 1 follow-up tumor assessment and who had no
protocol violations related to efficacy evaluation.
RESULTS
Forty-five patients were enrolled at four institutions
between November 2004 and August 2006. The study was
stopped short of the predefined target enrollment of 50
patients because accrual rate decreased over time. One patient
was excluded from all analyses because he was retrospec-
tively found to have metastatic colon cancer. The median
duration of follow-up in 44 eligible patients was 13.3 months
(range, 1–31 months). Most eligible patients were males and
had stage IV adenocarcinoma (Table 1). All had an ECOG
performance status of 0 or 1.
The median number of chemotherapy cycles was 4
(range, 1–6). Thirty-one patients received 4 cycles, including
four patients who received two additional chemotherapy
cycles because of the likelihood of continuous benefit as
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determined by the treating physician. Reasons for stopping
chemotherapy before four cycles were progressive disease
(n  10), noncompliance (n  2), and adverse event (n  1).
Nineteen doses were omitted, usually gemcitabine on day 8;
13 doses were reduced; and three were delayed. A total of 26
patients received maintenance bevacizumab, with a median
of 5 cycles (range, 1–23 cycles). Reasons for stopping main-
tenance bevacizumab were progressive disease (n  21),
adverse event (n  3), and unhealed wound after ankle
surgery (n  1); one patient continued to receive bevaci-
zumab at the time of evaluation.
Partial response was observed in 19 of 44 patients for
an objective response rate of 43% in the intent-to-treat anal-
ysis (95% confidence interval [CI], 26.3–60.1%; Table 2).
Sixteen patients had stable disease for a disease control rate
of 80% (95% CI, 72.0–87.0%). Of 39 patients who received
at least two cycles, 19 had partial responses (49%; 95% CI,
32.6–64.8%) and 16 had stable disease for a disease-control
rate of 90% (95% CI, 84.4–95.0%).
Median TTP, including two censored patients whose
disease had not progressed, was 5.5 months in the intent-to-treat
analysis of 44 patients (95% CI, 3.8–6.9 months; Figure 1).
Median survival, including 16 censored patients who remained
alive, was 13.7 months (95% CI, 7.3–21.8 months; Figure 2).
The 1-year survival rate was 55%.
The most common grade 3 or 4 hematologic adverse
event during combination therapy was neutropenia (9%; Ta-
ble 3). The most common grade 3 or 4 nonhematologic
adverse events were hypertension (11%), diarrhea (7%), dys-
pnea (7%), and thromboembolic events (7%). Thromboem-
bolic events occurred in three patients. The first had grade 4
ischemic bowel, necessitating discontinuation of all treatment
after the first cycle. The second had grade 3 acute coronary
event, necessitating discontinuation of bevacizumab after the
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FIGURE 1. Kaplan-Meier estimate of time to progression
(TTP, solid line) and 95% confidence interval (CI, dashed
lines) in intent-to-treat analysis of 44 patients with non-small
cell lung cancer, including two censored patients who did
not have progressive disease (data not shown).
TABLE 1. Patient and Disease Characteristics at Baseline in
44 Patients with NSCLC
Characteristic
Number of Patients (%), Unless
Otherwise Stated
Median age in years (range) 64.5 (42–81)
Sex
Males 31 (70)
Females 13 (30)
Race or ethnicity
Caucasian 29 (66)
Hispanic 12 (27)
African-American 2 (5)
Other 1 (2)
ECOG performance status
0 19 (43)
1 25 (57)
Disease stage
IIIB 8 (18)
IV or recurrent disease 36 (82)
Histology
Adenocarcinoma 25 (57)
Other 19 (43)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
TABLE 2. Best Response to Treatment in 44 Patients with
NSCLC
Type of Response Number of Patients (%)
Partial response 19 (43%; 95% CI, 26.3–60.1%)
Stable disease 16 (36%)
Progressive disease 8 (18%)
Not evaluablea 1 (2%)
CI, confidence interval; NSCLC, non-small cell lung cancer.
aNot evaluable because of discontinuation before completion of cycle 1 due to
adverse event.
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FIGURE 2. Kaplan-Meier estimate of overall survival (solid
line) and 95% confidence interval (CI, dashed lines) in in-
tent-to-treat analysis of 44 patients with non-small cell lung
cancer, including 16 censored patients who did not have
progressive disease (data not shown).
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first cycle but allowing continuation of gemcitabine and
oxaliplatin. The third had grade 3 pulmonary embolism and
bilateral deep venous thrombosis in the lower extremities,
which were judged possibly related to treatment by the
treating physician; the treatment was stopped because of
progressive disease. In addition, one patient had a grade 3
allergic reaction after the first cycle, characterized by dyspnea
and diaphoresis with grade 3 nausea and vomiting; treatment
was continued for a total of seven additional cycles of
bevacizumab. No patients experienced grade 3 or 4 neurop-
athy or nephrotoxicity.
Grade 3 adverse events during bevacizumab mainte-
nance were hypertension (4%), stroke (4%), and thrombocy-
topenia (4%). Specifically, bevacizumab was discontinued in
one patient after cycle 3 because of grade 3 hypertension and
in another patient after cycle 8 because of cerebellar hemor-
rhagic stroke with thrombocytopenia. In an additional patient,
bevacizumab was discontinued after cycle 9 because of grade
2 epistaxis.
DISCUSSION
At the time this study was conceived and implemented,
bevacizumab use in advanced NSCLC was experimental and,
at least in the United States, primarily limited to combination
with carboplatin and paclitaxel. Because of its favorable
safety profile6–10 and preliminary evidence of clinical activ-
ity,6–8 our goal was to test the efficacy and safety of oxali-
platin and gemcitabine with bevacizumab. Criteria were pre-
defined to decide whether this regimen, if proven tolerable,
would merit further testing in a phase III setting. To the best
of our knowledge, this is the first completed phase II trial of
this combination as first-line therapy in patients with ad-
vanced NSCLC.
Treatment was associated with tolerable toxicity in our
study. Although bevacizumab has been reported to increase
the hematologic toxicity of carboplatin with paclitaxel11,20
and cisplatin with gemcitabine,21 grade 3 or 4 hematologic
toxicity occurred in 10% of our patients. This finding was
consistent with the lower incidence of myelosuppression
secondary to oxaliplatin and gemcitabine compared with
other platinum-based doublets.6 The most common nonhe-
matologic event in our patients, hypertension, has been ob-
served in previous studies of bevacizumab in NSCLC11,20,21
and other solid tumors,22–24 usually responded to antihyperten-
sive therapy, and was reversible upon completing bevacizumab.
The lack of pulmonary hemorrhage in our study was
noteworthy. We followed the same exclusion criteria used in
the large phase III trials.11,20 Nevertheless, severe pulmonary
hemorrhage was noted in approximately 1% to 3% of those
patients, a rate too low for replication in our sample size. On
the other hand, concern about an increased risk of pulmonary
hemorrhage due to gemcitabine, perhaps related to thrombo-
cytopenia, was not substantiated in our study.
Two patients had hemorrhagic stroke, but one may not
have been related to treatment. The only other bleeding
events were grade 2 epistaxis during maintenance bevaci-
zumab and grade 1 events (data not shown). Therefore, the
incidence of grade 3 or 4 bleeding events was 5% in our
patients, approximating the 4% incidence in phase III stud-
ies.11,21 Three patients had thromboembolic events, including
one pulmonary embolism with bilateral deep venous throm-
bosis, one acute coronary event, and one ischemic bowel.
These complications have been described in patients with
NSCLC11,20,21 and other solid tumors.22–24 For example, in
the largest study of bevacizumab in patients with NSCLC
(N  1043),21 ischemic events, including arterial thrombo-
embolic events, occurred in 5% of patients who received
cisplatin with gemcitabine compared with 2% or 3% of those
who received the doublet plus bevacizumab 7.5 or 15 mg/kg,
respectively. The corresponding incidences of venous throm-
boembolic events were 6%, 7%, and 7%.21
Our response rate of 43% compared favorably with the
range of 25% to 31% associated with oxaliplatin and gem-
citabine alone in phase II studies6–8 and 30% to 35% asso-
ciated with bevacizumab and platinum-containing doublets in
randomized studies.11,20,21 The median TTP of 5.5 months
approached that in phase III trials,11,20,21 but did not meet the
predefined level of 6.7 months for further evaluation. Six
additional patients were needed to satisfy the target sample
size of 50 patients, and it remains unclear whether enrolling
those additional patients would have significantly altered the
outcome. The median duration of survival of 13.7 months
was quite promising and, again, comparable to that of plati-
num doublets with bevacizumab in previous trials.11,20 Nev-
ertheless, survival data must be interpreted cautiously in
phase II studies, even when conducted at multiple institu-
tions, and was not the primary end point of our study.
Oxaliplatin-based doublets continue to be evaluated as
first-line therapy in patients with advanced NSCLC. Oxali-
TABLE 3. Grade 3 or 4 Adverse Events
Adverse Event
Number of Patients (%)
Gemcitabine,
Oxaliplatin,
Bevacizumab
(n  44)
Grade 3 or 4a
Maintenance
Bevacizumab
(n  26)
Grade 3 or 4
Hematologic events
Neutropenia 4 (9)a 0
Thrombocytopenia 3 (7)a 1 (4)
Anemia 1 (2) 0
Nonhematologic events
Hypertension 5 (11)a 1 (4)
Diarrhea 3 (7) 0
Dyspnea 3 (7) 0
Thromboembolic events 3 (7)a 0
Fatigue 2 (5) 0
Nausea and vomiting 2 (5) 0
Stroke (hemorrhagic) 1 (2)ab 1 (4)
Allergic reaction 1 (2) 0
Neuropathy (sensory) 1 (2)c 0
aEach asterisk indicates 1 grade 4 event.
bOne stroke was considered not related to treatment; the other was probably related
to maintenance bevacizumab.
cOne patient had grade 2 neuropathy; none had grade 3 or 4 neuropathy.
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platin with gemcitabine had similar activity and milder he-
matologic toxicity compared with carboplatin and gemcitab-
ine or the same regimen followed by docetaxel in a large
phase II randomized study.6 Oxaliplatin and pemetrexed also
showed efficacy comparable to that of carboplatin and pem-
etrexed in a prior trial.10 Oxaliplatin with docetaxel showed
promising results in a recent pilot study25; and this combina-
tion is now being studied with the addition of bevacizumab in
an ongoing multicenter phase II trial. Lastly, and importantly,
a phase III study of gemcitabine plus either oxaliplatin or
carboplatin (or cisplatin) has been completed and results are
pending.
In summary, oxaliplatin and gemcitabine with bevaci-
zumab was reasonably well tolerated, showed efficacy similar
to that of other platinum doublets in combination with bev-
acizumab, and represents another treatment option in our
armamentarium for patients with advanced NSCLC. Further
phase III trials will depend on the results of ongoing and
recently completed trials.
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